Drug Sponsors

Boston Scientific opens China Innovation Center

Wednesday, September 18, 2013 11:25 AM

Boston Scientific, a global medical technology company, has opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) as well as its new Innovation Center. Boston Scientific expects to foster local talent while sustainably developing innovative technologies uniquely suited to the China market.

More... »

Cardiome, Tzamal Medical form commercialization agreement

Wednesday, September 18, 2013 10:57 AM

Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.

More... »

Chiesi to acquire 100% of Cornerstone Therapeutics

Wednesday, September 18, 2013 09:04 AM

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

More... »

Celtaxsys restructures, enhances operational focus

Monday, September 16, 2013 08:43 AM

Celtaxsys, an Atlanta-based pharmaceutical discovery and development company, has restructured its management and operations to focus on development of its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis.

More... »

Recordati acquires Laboratorios Casen Fleet

Wednesday, September 11, 2013 01:40 PM

Recordati, an international pharmaceutical group, has acquired Laboratorios Casen Fleet, a Spanish pharmaceutical company headquartered in Madrid with production facilities in Zaragoza. The transaction is valued at $123.3 million and will be funded from existing liquidity.

More... »

Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013 01:31 PM

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento's common stock. Reflecting Sorrento's recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

More... »

Sorrento Therapeutics licenses Biomiga Diagnostics' drug monitoring device

Wednesday, September 11, 2013 01:26 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has secured an exclusive license for the worldwide rights to Biomiga Diagnostics' proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento's late-stage compound, Cynviloq (paclitaxel polymeric micelle).

More... »

Baxter acquires Gambro

Monday, September 9, 2013 03:49 PM

Baxter International has acquired Sweden-based Gambro, a privately-held global medical technology company and producer of dialysis products.

More... »

Nuclea Biotechnologies acquires Oncogene Science, extends Wilex cooperation

Monday, September 9, 2013 12:05 PM

Pittsfield, Mass.-based Nuclea Biotechnologies has acquired all shares of Cambridge, Mass.-based Wilex (Oncogene Science), a wholly owned U.S. subsidiary of Wilex.

More... »

Eisai, Clinigen partner on patient access program in Germany

Monday, September 9, 2013 11:56 AM

Eisai EMEA, an R&D based pharmaceutical company, has established a named patient access program to ensure patients continue to receive an uninterrupted supply of the anti-epilepsy drug Fycompa (perampanel), following the temporary suspension of commercial distribution in Germany. The access program will be managed by Clinigen Global Access Programs (GAP), a U.K.-headquartered specialty global pharmaceutical company.

More... »